Published in J Histochem Cytochem on July 24, 2006
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci (2008) 1.48
Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. Biochem Biophys Res Commun (2011) 1.25
Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci U S A (2007) 1.22
Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord (2014) 1.21
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One (2010) 1.11
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. J Pharmacol Exp Ther (2008) 1.09
Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem (2011) 1.03
Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues. J Histochem Cytochem (2010) 1.01
Revealing the molecular layer of the primate dorsal cochlear nucleus. Neuroscience (2008) 0.98
Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol (2010) 0.95
Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem (2009) 0.93
Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo. Neuropharmacology (2009) 0.90
PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging (2013) 0.89
Synthesis and in vitro biological evaluation of pyrazole group-containing analogues for PDE10A. Medchemcomm (2013) 0.86
De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions. Am J Hum Genet (2016) 0.86
Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. Bioorg Med Chem (2014) 0.86
Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse (2014) 0.83
cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol (2011) 0.81
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. Oncogene (2014) 0.81
Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. Basal Ganglia (2013) 0.81
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging (2012) 0.80
Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate. J Med Chem (2015) 0.79
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications. Neuropharmacology (2014) 0.79
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. Curr Pharm Des (2015) 0.78
Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32(1,2,3). eNeuro (2015) 0.78
PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways. Pharmacol Res Perspect (2014) 0.78
Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways. J Neurosci (2015) 0.78
β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget (2016) 0.77
Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One (2015) 0.77
Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET. Pharmaceuticals (Basel) (2012) 0.77
Phosphodiesterase regulation of alcohol drinking in rodents. Alcohol (2015) 0.77
Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. Am J Hum Genet (2016) 0.76
Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation. Transl Psychiatry (2014) 0.76
Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice. Psychopharmacology (Berl) (2013) 0.76
Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HDQ175/Q7 Mice. J Huntingtons Dis (2016) 0.75
Molecular Imaging Markers to Track Huntington's Disease Pathology. Front Neurol (2017) 0.75
Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primates. Pharmacol Res Perspect (2016) 0.75
Characterization of [(11)C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. Eur J Nucl Med Mol Imaging (2016) 0.75
A novel thermoregulatory role for PDE10A in mouse and human adipocytes. EMBO Mol Med (2016) 0.75
Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain. Drug Deliv (2013) 0.75
Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells. Acta Pharmacol Sin (2016) 0.75
Identification and Localization of the Cyclic Nucleotide Phosphodiesterase 10A in Bovine Testis and Mature Spermatozoa. PLoS One (2016) 0.75
Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography. J Biomol Screen (2013) 0.75
Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches. Exp Ther Med (2016) 0.75
Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. Transl Psychiatry (2016) 0.75
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile. Neuropharmacology (2016) 0.75
Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia. Pharmacol Res Perspect (2016) 0.75
Bioactivities of Compounds from Elephantopus scaber, an Ethnomedicinal Plant from Southwest China. Evid Based Complement Alternat Med (2014) 0.75
Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study. Transl Psychiatry (2017) 0.75
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. PLoS One (2017) 0.75
Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl) (2016) 0.75
Potential drug targets and treatment of schizophrenia. Inflammopharmacology (2017) 0.75
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Photochemical transformations of pyridinium salts: mechanistic studies and applications in synthesis. Org Biomol Chem (2007) 3.12
An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol Pathol (2011) 2.21
Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov (2006) 2.10
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs (2007) 1.95
Guiding principles for site selective and stereoselective intermolecular C-H functionalization by donor/acceptor rhodium carbenes. Chem Soc Rev (2011) 1.80
International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies. Toxicol Pathol (2010) 1.71
Immunohistochemical localization of PDE10A in the rat brain. Brain Res (2003) 1.61
Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod (2009) 1.59
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology (2006) 1.53
Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron (2005) 1.51
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A (2012) 1.49
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology (2006) 1.44
PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res (2008) 1.32
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J Med Chem (2009) 1.31
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci U S A (2009) 1.30
Evaluation of organ weights for rodent and non-rodent toxicity studies: a review of regulatory guidelines and a survey of current practices. Toxicol Pathol (2007) 1.30
Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. Toxicol Pathol (2007) 1.24
Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. Nat Prod Rep (2008) 1.15
Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol (2004) 1.14
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One (2010) 1.11
Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis. Mol Autism (2011) 1.11
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. J Pharmacol Exp Ther (2008) 1.09
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord (2008) 1.08
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem (2007) 1.06
Novel aromatase inhibitors by structure-guided design. J Med Chem (2012) 1.03
Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). BioDrugs (2014) 1.03
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg Med Chem Lett (2004) 1.03
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Drug Metab Dispos (2012) 1.02
Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology (2007) 1.02
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther (2010) 1.00
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther (2007) 0.99
Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci U S A (2008) 0.99
Nonclinical safety strategies for stem cell therapies. Toxicol Appl Pharmacol (2012) 0.98
Social dominance in female monkeys: dopamine receptor function and cocaine reinforcement. Biol Psychiatry (2012) 0.97
Glycine transporter inhibition reverses ketamine-induced working memory deficits. Neuroreport (2010) 0.96
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther (2012) 0.96
A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer (2010) 0.94
Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem (2009) 0.93
A fluorous-tagged linker from which small molecules are released by ring-closing metathesis. J Org Chem (2008) 0.92
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation. Toxicol Pathol (2009) 0.89
An efficient method for synthesising unsymmetrical silaketals: substrates for ring-closing, including macrocycle-closing, metathesis. Org Biomol Chem (2008) 0.88
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology (2003) 0.88
Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J Pharmacol Exp Ther (2009) 0.88
Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage (2010) 0.88
Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol Dis (2009) 0.88
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol (2003) 0.88
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg Med Chem Lett (2009) 0.87
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology (2011) 0.87
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl) (2010) 0.87
Spontaneous and age-related testicular findings in beagle dogs. Toxicol Pathol (2008) 0.85
Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology (2009) 0.85
High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain. J Neurosci Methods (2011) 0.84
Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry (2002) 0.84
PDE4 as a target for cognition enhancement. Expert Opin Ther Targets (2013) 0.84
PDE inhibition and cognition enhancement. Expert Opin Ther Pat (2012) 0.84
C-H functionalization: collaborative methods to redefine chemical logic. Angew Chem Int Ed Engl (2014) 0.83
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav Brain Res (2010) 0.83
The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav Pharmacol (2007) 0.83
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem (2009) 0.83
Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology (2007) 0.83
Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol Sci (2013) 0.83
Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. Neurobiol Learn Mem (2012) 0.83
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J Med Chem (2012) 0.82
Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF). J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.82
STP position paper: ovarian follicular counting in the assessment of rodent reproductive toxicity. Toxicol Pathol (2005) 0.81
Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands. Lab Invest (2004) 0.81
Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma. Biomarkers (2012) 0.81
A strategy for risk management of drug-induced phospholipidosis. Toxicol Pathol (2009) 0.81
Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action. Mol Autism (2013) 0.81
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology (Berl) (2013) 0.81
Human safety risk assessment of lymph node angiomas observed in 2-year carcinogenicity studies in rats. Regul Toxicol Pharmacol (2012) 0.80
Defects in embryonic development of EGLN1/PHD2 knockdown transgenic mice are associated with induction of Igfbp in the placenta. Biochem Biophys Res Commun (2009) 0.80
An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett (2009) 0.80
Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. Expert Opin Drug Discov (2007) 0.80